2006 JASN IMPACT FACTOR 7.371	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007091030v1 19/4/743    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Feldt, S. Articles by Muller, D. N. PubMed PubMed Citation Articles by Feldt, S. Articles by Muller, D. N.

The Putative (Pro)renin Receptor Blocker HRP Fails to Prevent (Pro)renin Signaling

Sandra Feldt^*, Ulrike Maschke, Ralf Dechend^*, Friedrich C. Luft^*, and Dominik N. Muller^*,

^* Medical Faculty of the Charité, Experimental and Clinical Research Center, Franz Volhard Clinic, and HELIOS Klinikum Berlin-Buch, Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany

Correspondence: Dr. Dominik N. Muller, Experimental and Clinical Research Center, Max-Delbruck-Center, Lindenberger Weg 80, 13125 Berlin, Germany. Phone: +49-30-9406-4581; Fax: +49-30-9406-4220; E-mail: dominik.mueller{at}mdc-berlin.de

Received for publication September 23, 2007. Accepted for publication November 22, 2007.

The prorenin/renin receptor is a recently discovered component of the renin-angiotensin system. The effects of aliskiren, a direct inhibitor of human renin, were compared with the handle region decoy peptide (HRP), which blocks the prorenin/renin receptor, in double-transgenic rats overexpressing the human renin and angiotensinogen genes. After 7 wk, all aliskiren-treated rats were alive, whereas mortality was 40% in vehicle-treated and 58% in HRP-treated rats. Aliskiren but not the HRP reduced BP and normalized albuminuria, cystatin C, and neutrophil gelatinase-associated lipocalin, a marker of renal tubular damage, to the levels of nontransgenic controls. In vitro, human renin and prorenin induced extracellular signal–regulated kinase 1/2 phosphorylation, independent of angiotensin II (AngII), in vascular smooth muscle cells. Preincubation with the HRP or aliskiren did not prevent renin- and prorenin-induced extracellular signal–regulated kinase 1/2 phosphorylation, whereas the MAP kinase kinase (MEK1/2) inhibitor PD98059 prevented both. In conclusion, renin inhibition but not treatment with the HRP protects against AngII-induced renal damage in double-transgenic rats. In addition, the in vitro data do not support the use of the HRP to block AngII-independent prorenin- or renin-mediated effects.

This article has been cited by other articles:

				G. Nguyen and A. H. J. Danser Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents Exp Physiol, May 1, 2008; 93(5): 557 - 563. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673